I'd be surprised if there haven't been offers to license MPL. The initial fee would fund the study but the milestone payments are only realised after approval. Therefore licensing offers a low risk opportunity for BP to participate in a potential blockbuster. If MPL gains FDA approval the greater returns to shareholders will always be gained by avoiding licensing deals and selling the whole thing. I would prefer to wait and see this thing through. It will be worth billions if successful.
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman, page-59
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.005(2.63%) |
Mkt cap ! $94.89M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 19.0¢ | $58.40K | 305.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 115000 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 86074 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |